Aurora-GT
Author: Stephanie Yip
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells), which is intended to rebuild blood vessels in the lung. Administering this gene therapy involves isolating a PAH patient’s autologous endothelial progenitor cells, transfecting the cells with the gene for human endothelial NO-synthase, prior to their ex-vivo expansion, and reintroducing them into the same patient.
Analyst Outlook
United Therapeutics is aiming to diversify its pulmonary hypertension (PH) portfolio with a pipeline gene therapy product, Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells). The company stands out as the only one with a late-phase gene therapy in development. If successful, this therapy could address critical unmet need in the PH market for options beyond symptomatic treatment. Datamonitor Healthcare awaits further developments for Aurora-GT, as Phase II/III clinical trial data are yet to be released.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Aurora-GT : Pulmonary hypertension
LIST OF FIGURES
8 Figure 1: Aurora-GT for pulmonary hypertension – SWOT analysis
LIST OF TABLES
5 Table 1: Aurora-GT drug profile
7 Table 2: Aurora-GT Phase II trial in pulmonary hypertension
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
INOpulse 
Sign up to the